RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Cell Therapy completed a $40 million Series C1 financing, led by China Industrial Asset Management, which contributed $26 million of the total. Shanghai Cell Therapy is developing oncology drugs based on precision medicine and cell therapy technologies. The company has established the Shanghai Wu Mengchao-Nobel Laureate Joint Medical Technology and Innovation Center. It claims the center has developed over 45 immune cell technologies and been awarded 16 China and two American patents.
Source: China Biotoday
